Member Info for Notpotalot

Err, actually no Nick. 😃

I bought in heavily at the lows and now have a very healthy average.

If you genuinely believe in a company’s potential, you accept placings are part of the game. It’s all about timing your buys – I’ll explain it to you sometime.

As regards Mark E delivering – check your Xmas stocking in a few weeks.

The key is being a holder when the SP explodes. No warning, no heads-up - it just happens. But when it does and it will, you too will have a happy face - if you’re holding Val.

G’night. Pleasant dreams.

“Stay in says Nick” - like we weren’t going to. LOL

Even he admits the SP is only going one way, but get out before April, he says.

Why? The SP is climbing daily, yet only holding RNSs have been released since the placing.

8-10 RNS updates on multiple projects are likely to be announced before March, a couple of which have the potential to make Val headline material across the financial press. If you are nervous Nick, put your money into a savings account. Nick – the dithering dealer!

ValiRx’s share price has quietly climbed over 30% in the last week, on no news.

With RNS updates now pending across the pipeline, and funding secured for the months ahead, the 0.5p warrants are now in sight but that is just a start point. The 1.3p warrants are next and with every warrant actioned, the runway is further extended. When headline news arrives, even a 3rd Heathrow runway could fall short by comparison. ✈️

On Monday, Gilead bought Sprint’s TREX1 preclinical cancer immunotheraphy programme for a potential $400m. Prior to this, the entire Swedish company was only valued at c$15-$20m and the sale just involved one of their assets.

The new agreement calls for Gilead to pay Sprint $14 million up front and as much as $400 million more if the program meets certain clinical, regulatory and commercial milestones.

Once the imminent CLX and Blue Ribbon Bio (VAL201) patents are secured, early partnering is on the cards for both. As in the Sprint deal, any partnership may only involve one or maybe both of these assets, leaving multiple other assets and the Inaphaea lab on a free ride. Of course, it may be that the interested party looks at the total Val package and buys lock, stock and barrel.

Must admit, I wasn’t expecting the climb to start already.

You would have thought it would have needed some of the RNSs probably being prepared at this very moment. Apparently not.

The placing hiccup was inconvenient but has given our CEO the breathing space he needed to place the final pieces in the Val jigsaw.

There will certainly be sells as many traders will gladly accept a 30%-100% profit over the next few weeks. Then, when the ask passes 0.6p the warrants will give some traders another opportunity to cash in, while extending the runway yet further.

All inevitable and all part of the game. Pass the popcorn. 😜

Such a relief to hear that ABftse believes Val is undervalued. 🤣🤣🤣

I'm sure all holders were really worried before that!

Wot a plonker. 🤣🤣🤣

Porky, If I may interject, when you are going to slag off a share, at least use a modicom of fact in your posts.

Since Mark E's arrival, the main function of the lab has been to build data into CLX, 201, 401 and a host of evaluations. He has made that clear on numerous occasions.

What a silly billy you are! 🤫

Lol. You lot do realise that spending so much effort slagging off a share you aren't invested in, just reinforces the belief that Val is the place to be.

Thanks 👍😀👍😀

Send in the clowns!

Tortured souls whose life revolves around desperately wanting to destroy a company targeting cancer (and failing miserably).

I hope you don't have a mouthful of popcorn when a big RNS hits. Could pebble dash your caravan. 🤣

The desperation of de-rampers is hilarious. Much to their dismay, only a handful of traders have sold over recent weeks.

Even with Nick, Porky and Rat's concerted efforts, too many are now happy to wait for that partnering RNS or any one of the several sources of good news now imminent.

As a kid, I used to enjoy building things with Lego.

I guess a few on here, bereft of construction skills, obtained their kicks from knocking things down.

They’ve kind of approached life the same way!

Some sad people out there!

Funny how the uninvested focus on the money. It’s not a trading share, get over it!

The science, however, is amazing. Another great RNS as ValiRX builds towards the future.

Exciting times!

I wonder what goodies Mark will bring Val back from his presentations in Carlsbad and San Diego? An early partner for CLX? Quite possibly, as promoting Val’s flagship asset is the purpose of his visits. We already know from Mondays RNS “ValiRx is in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company”.

While CLX is the main subject matter, you can be sure that while over there, he won’t miss an opportunity to discuss other Val assets. After all, we have multiple candidates across the whole cancer spectrum. Although a leading scientist, Mark is also an experienced businessman with a strong personal interest in the company. Once a salesman, always a salesman.

Another green contributor.

Speaking of which, I must put some manure onto the garden

Spot on , Uncanny.

Like many other holders, now binned posts from the non-invested. Riff-raff with nothing valid to contribute so why bother reading their garbage. Might need to get a new green ink cartridge for my screen though. Haha

I asked Mark the same question. Still a bit of work to do but we can expect a webinar to update when a few more pieces are in place.

Being Friday, it could be Monday.

Well done anyway. A shrewd buy at these silly prices.

AIMO, GLA

Having taken his profits again, we can be sure Mr Slater will desperately be trying to drive the SP down to get back in. A flurry of posts can be expected over the coming days.

Wouldn’t it be a shame if Val dropped a blockbuster RNS out of the blue?

Good decisions Uncanny and LTR.

Commiserations Porky. Lol